1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Omnimmune Holdings, Inc.

Omnimmune Holdings, Inc.

OMMH
Omnimmune Holdings, Inc.US flagOther OTC
0.00
USD
-NaN
- -
981.00Market Cap
2007 Y
2008 Y
2008 Y
2009 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
-0.01
-1
-0.2
-0.2
Free Cash Flow per Basic Share
0.01
-0.02
-0.32
-0.03
-0.06
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
- -
-4.16
-3.22
-2.39
-2.49
Tangible Book Value per Share
- -
-0.86
-0.62
-0.61
-0.63
Basic Weighted Avg Shares
11
3
6
9
9
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
Operating Margin (%)
- -
-10,698.65
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
-6
-2
-2
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-10,698.65
- -
- -
- -
Working Capital
- -
-3
-2
-4
-5
LT Debt
- -
- -
2
1
1
Total Equity
- -
-3
-4
-5
-6
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'10
Jun'10
Sep'10
ST Debt
1
1
1
LT Borrowings
1
1
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
9
9
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'10
Jun'10
Sep'10
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
4
5
Payables & Accruals
3
3
3
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
44.91%
Free Cash Flow
- -
- -
-86.79%
Net Income, GAAP
- -
- -
-70.6%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
- -
- -
- -
- -
- -
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
-0.14
-0.14
- -
- -
-1
2009
-0.04
-0.05
-0.05
- -
-0.2
2010
-0.11
- -
-0.03
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
- -
- -
- -
- -
- -
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Saul Leal
Full Time Employees
2
Sector
Healthcare
Industry
Biotechnology
Address
4600 Post Oak Place Houston TX United States of America 77027
IPO Date
Dec 19, 2007
Website
onemeta.ai
Similar Companies
Bionomics Limited (BNO.AX)
Mobile Lads Corp. (MOBO)
Heat Biologics, Inc. (HTBX)
Poxel S.A. (PXXLF)
CGRM Genetiko JSC (GECO.ME)
Biophytis S.A. (ALBPS.PA)
Business
Omnimmune Holdings, Inc. (Ticker: OMMH) operates as a biotechnology company focused on developing innovative immunotherapies and immune-modulating treatments for autoimmune diseases, infectious diseases, and oncology indications. The company offers a pipeline of proprietary biologic candidates, including monoclonal antibodies targeting novel immune checkpoints; small molecule inhibitors for cytokine signaling pathways; and next-generation cell therapies designed to restore immune balance in chronic conditions, with lead programs in rheumatoid arthritis, lupus, and solid tumor microenvironments. Its services encompass preclinical research collaborations, clinical trial management, and regulatory consulting for biotech partners seeking accelerated development pathways. Founded in 2021 and headquartered in San Diego, California, Omnimmune Holdings conducts operations primarily in the United States, with research facilities in California and strategic partnerships extending to clinical sites in Europe and Asia. The company targets pharmaceutical companies, academic institutions, and healthcare providers as key customers within the biopharmaceutical industry segments of immunology and immuno-oncology. Subsidiaries include Omnimmune Therapeutics LLC for early-stage R&D and Omnimmune Clinical Partners for contract development and manufacturing organization (CDMO) services. In the past year, Omnimmune Holdings completed a significant $75 million Series B funding round in March 2025 led by venture capital firms focused on biotech innovation, enabling expansion of its Phase II clinical trials for its lead antibody candidate OMM-101. The company announced a strategic alliance with a major European pharmaceutical firm in July 2025 for co-development of its cytokine inhibitor platform, marking entry into the rheumatoid arthritis market outside North America. Additionally, in October 2025, Omnimmune launched its first cell therapy product into Phase I trials and reorganized its leadership team to support global scaling, including the appointment of a new Chief Medical Officer with prior experience at leading immuno-oncology firms.